ABSTRACT
INTRODUCTION Determining significant metabolic changes in Dementia with Lewy Bodies (DLB), a complex and multifactorial neurodegenerative disease, requires, in addition to the analysis of concentration changes, a deep understanding of functional modifications in the context of metabolic networks.
METHODS Brain metabolomics data from DLB patients and controls was explored using novel correlation analysis approaches to identify metabolites with the largest changes in their network in the disease state.
RESULTS Novel clustering and correlation network analysis shows major change in the metabolic network in DLB brain relative to matching controls with the largest interaction network alterations for fructose, propylene- glycol, pantothenate and O-acetylcarnitine in spite of no statistically significant changes in their concentrations.
DISCUSSION Network and correlation analyses indicate major changes in the purine degradation pathway, propanoate and β-alanine metabolism as well as an increased role of fructose and reduced significance of glucose in DLB affected brain.
Competing Interest Statement
S.F.G. is supported by grants from the National Institute of Neurological Disorders and Stroke (1R01NS110838- 01A1), the National Institutes on Aging (1R21AG067083-01) and the Michael J. Fox Foundation (MJFF16201). All other authors declare no perceived or true conflicts of interest.
Funding Statement
S.F.G. is supported by grants from the National Institute of Neurological Disorders and Stroke (1R01NS110838- 01A1), the National Institutes on Aging (1R21AG067083-01) and the Michael J. Fox Foundation (MJFF16201).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Beaumont Health Systems Human Investigation Committee (HIC No.: 2018-387).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
